Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhage urinary tract24.07.01.007; 20.02.03.0050.000224%Not Available
Varices oesophageal24.10.02.004; 09.01.06.009; 07.15.05.0010.000112%Not Available
Fluid intake reduced14.05.10.0010.000246%Not Available
Pulmonary mass22.02.07.0040.000750%Not Available
Temperature intolerance08.01.09.0220.000437%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000817%Not Available
Cancer pain16.32.03.0040.000168%Not Available
Metabolic disorder14.11.01.001--Not Available
Dysgraphia17.02.03.0060.000112%Not Available
Eyelash discolouration06.06.04.0090.000627%Not Available
Hyperalbuminaemia14.10.01.007--Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000168%Not Available
Angiopathy24.03.02.0070.000302%Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.001847%Not Available
Extremity necrosis24.04.03.0120.000112%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000694%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Jugular vein distension02.11.04.011; 24.03.04.0050.000168%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Ischaemic cerebral infarction24.04.06.013; 17.08.01.0220.000112%Not Available
Neurological symptom17.02.05.0100.000302%Not Available
Appetite disorder19.09.01.002; 14.03.01.0040.000761%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000638%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.001164%Not Available
Embolism24.01.01.009--
Infarction24.04.02.0170.000224%Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 21 Pages